A new analysis indicates that rates of high-grade cervical lesions decreased in young US women after vaccines were made available to protect against human papillomavirus (HPV), but the trend may be due in part to changes in cervical cancer screening recommendations. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study illustrates some of the challenges in monitoring a vaccine’s impact during a time of concurrent changes in screening.
A new analysis indicates that rates of high-grade cervical lesions decreased in young US women after vaccines were made available to protect against human papillomavirus (HPV), but the trend may be due in part to changes in cervical cancer screening recommendations. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study illustrates some of the challenges in monitoring a vaccine’s impact during a time of concurrent changes in screening.
More than half of high-grade cervical lesions, which are abnormal tissue changes that can lead to cancer, are caused by persistent HPV infection that can be prevented if a person receives an HPV vaccine. Monitoring trends in the incidence of these lesions is helpful for evaluating the impact of HPV vaccination.
A team led by Susan Hariri, PhD, of the US Centers for Disease Control and Prevention, found that in the first few years after HPV vaccination was introduced in the United States (2008-2012), there were large and uniform declines in high-grade cervical lesions in young women across the country who were aged 18 to 20 years, and to a lesser extent, in women aged 21 to 24 years.
Dr. Hariri noted that high-grade cervical lesions are asymptomatic and can only be detected through routine cervical cancer screening. Because screening recommendations were changing during the time period of this study, the investigators also looked at trends in cervical cancer screening utilization. “In particular, screening is no longer recommended in women before age 21 years, and we found substantial declines in screening in 18 to 20 year olds that were consistent with the new recommendations,” said Dr. Hariri. While screening also declined in 21 to 24 year old women, the decreases in screening were much smaller. “We think that the decreases in high-grade lesions in this group reflect changes in screening but also may be partially due to HPV vaccination.” Dr. Hariri added that the greatest benefit of HPV vaccination—reducing the burden of cervical cancer and other HPV-associated cancers—will take many years to evaluate because of the long lag time between infection with HPV and the development of cancer.
In an accompanying editorial, Harinder Brar, MD and Allan Covens, MD, of the University of Toronto, stated that the study is significant because it is the first to look at the incidence trends of high-grade cervical lesions in the post-vaccination era. “The study highlights that while preliminary data demonstrates a drop in… incidence rates, the results may be confounded by the changes in cervical screening guidelines.”
Article: “Population-based trends in high-grade cervical lesions in the early HPV vaccine era, United States.” Susan Hariri, Michelle L. Johnson, Nancy M. Bennett, Heidi Bauer, Ina Park, Sean Schafer, Linda M. Niccolai, Elizabeth R. Unger, Lauri E. Markowitz, and the HPV-IMPACT Working Group. CANCER; Published Online: June 22, 2015 (DOI: 10.1002/cncr.29266).
Additional Information
Full Citation: “Trends in CIN2+ post HPV Vaccination: The Devil is in the Details.” Harinder Brar and Allan Covens. CANCER; Published Online: June 22, 2015 (DOI: 10.1002/cncr.29264).
Link to study: http://doi.wiley.com/10.1002/cncr.29266
Author Contact: Brian Katzowitz, of the CDC’s News Media Team, at bkatzowitz@cdc.gov or (404) 639-1470
or Mobile (404) 455-9924.
About Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online at http://wileyonlinelibrary.com/journal/cancer.
Follow us on Twitter @JournalCancer and Facebook https://www.facebook.com/ACSJournals
About Wiley
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders.
Dawn Peters
+1 781-388-8408
sciencenewsroom@wiley.com